Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: pozelimab, olendalizumab, pexelizumab +10 | 0.90 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 58 Parkinson's papers of 29,539 | 0.46 |
| pathways Reactome | 5 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 6296
Sealed predictions
- C5 in dopamine neurons, braak+0.08 (p 0.839) → +0.17 (p 0.665)receipt 6303
Swarm cases
receipt 6303: C5 in dopamine neurons, braak
- power
- full sample +0.25 (p 0.315, n 18), 95% CI -0.24 to +0.64. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.25 (p 0.315, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.27 (p 0.277, n 18). could be the mix.
- skeptic
- leave-one-out range +0.19 to +0.43, sign flips 0; without severely affected donors +0.25 (p 0.315, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for C5 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts